Quantum Competitors
| QNTM Stock | 3.64 0.01 0.27% |
Quantum BioPharma vs Evaxion Biotech Correlation
Very poor diversification
The correlation between Quantum BioPharma and EVAX is 0.85 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Quantum BioPharma and EVAX in the same portfolio, assuming nothing else is changed.
Moving against Quantum Stock
| 0.72 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.69 | DRTS | Alpha Tau Medical | PairCorr |
| 0.68 | CMB | Cambium Bio | PairCorr |
| 0.62 | GXEA | Galapagos NV | PairCorr |
| 0.59 | PYC | Physiomics Plc | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Quantum BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Quantum BioPharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Quantum BioPharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Quantum and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Quantum BioPharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Quantum Stock performing well and Quantum BioPharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Quantum BioPharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 5.40 | (0.80) | 0.00 | (0.81) | 0.00 | 10.71 | 57.05 | |||
| ANVS | 5.09 | 0.45 | 0.08 | 0.82 | 5.15 | 14.79 | 41.06 | |||
| CPIX | 4.20 | 1.10 | 0.25 | 0.88 | 3.72 | 12.60 | 29.09 | |||
| PYPD | 1.99 | 0.24 | 0.09 | 0.36 | 2.13 | 4.79 | 14.82 | |||
| RMTI | 3.87 | 0.05 | 0.00 | 0.35 | 4.36 | 6.38 | 40.19 | |||
| RNTX | 3.67 | (0.45) | 0.00 | (0.30) | 0.00 | 9.52 | 22.23 | |||
| CELU | 3.37 | (0.48) | 0.00 | (0.34) | 0.00 | 10.29 | 26.97 | |||
| BCAB | 7.52 | (1.52) | 0.00 | 0.98 | 0.00 | 15.28 | 66.15 | |||
| ATNM | 2.90 | (0.24) | 0.00 | (0.44) | 0.00 | 5.84 | 20.75 | |||
| EVAX | 4.51 | (0.85) | 0.00 | (1.19) | 0.00 | 9.15 | 37.88 |
Cross Equities Net Income Analysis
Compare Quantum BioPharma and related stocks such as Reviva Pharmaceuticals, Annovis Bio, and Cumberland Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (39.3 M) | (29.9 M) | (26.9 M) | (25.6 M) |
| ANVS | (369.6 K) | (4.7 M) | (8.3 M) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (713.9 K) | (991 K) | (5.5 M) | (14.5 M) | (25.1 M) | (56.2 M) | (24.6 M) | (22.1 M) | (21 M) |
| CPIX | 2 M | 5.7 M | 5.8 M | (2.1 M) | 2.4 M | 731.4 K | (944.7 K) | (8 M) | (7 M) | (3.5 M) | (3.3 M) | (3.5 M) | (5.6 M) | (6.3 M) | (6.5 M) | (5.8 M) | (5.5 M) |
| PYPD | (1.8 M) | (1.8 M) | (1.8 M) | (3.9 M) | (8.2 M) | (8.2 M) | (11.4 M) | (54.5 M) | 5.9 M | (6.9 M) | (35.3 M) | (40.7 M) | (39.5 M) | (23.9 M) | (29 M) | (34.2 M) | (35.9 M) |
| RMTI | (1.9 M) | (21.4 M) | (54 M) | (48.8 M) | (21.3 M) | (14.4 M) | (19.8 M) | (25.9 M) | (32.1 M) | (34.1 M) | (30.9 M) | (32.7 M) | (18.7 M) | (8.4 M) | (480 K) | (432 K) | (453.6 K) |
| RNTX | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (21.2 K) | (26.2 K) | (27.3 K) | (15.7 K) | (62.9 M) | (56.6 M) | (53.8 M) |
| CELU | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (211.9 M) | (208.2 M) | (100.1 M) | 14.2 M | (196.3 M) | (57.9 M) | (66.6 M) | (69.9 M) |
| BCAB | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29.8 M) | (35.9 M) | (95.4 M) | (105.3 M) | (123.5 M) | (69.8 M) | (62.8 M) | (65.9 M) |
| ATNM | (18.4 K) | 10.3 K | (8.4 M) | (10.8 M) | (24.7 M) | (21 M) | (24.3 M) | (26.6 M) | (23.7 M) | (21.9 M) | (22.2 M) | (24.8 M) | (33 M) | (48.8 M) | (38.2 M) | (34.4 M) | (32.7 M) |
| EVAX | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (11.2 M) | (15 M) | (24.5 M) | (23.2 M) | (22.1 M) | (10.6 M) | (9.5 M) | (10 M) |
Quantum BioPharma and related stocks such as Reviva Pharmaceuticals, Annovis Bio, and Cumberland Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Quantum BioPharma financial statement analysis. It represents the amount of money remaining after all of Quantum BioPharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Quantum BioPharma Competitive Analysis
The better you understand Quantum BioPharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Quantum BioPharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Quantum BioPharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Quantum BioPharma Competition Performance Charts
Five steps to successful analysis of Quantum BioPharma Competition
Quantum BioPharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Quantum BioPharma in relation to its competition. Quantum BioPharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Quantum BioPharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Quantum BioPharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Quantum BioPharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Quantum BioPharma position
In addition to having Quantum BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 73 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Quantum BioPharma Correlation with its peers. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Quantum diversify its offerings? Factors like these will boost the valuation of Quantum BioPharma. Anticipated expansion of Quantum directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Quantum BioPharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Quantum BioPharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Quantum BioPharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Quantum BioPharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.